Abstract
Recent studies show that long non-coding RNAs (lncRNAs) may be significant functional regulators in tumor development, including bladder cancer. Here, we found that PVT1 was upregulated in bladder cancer tissues and cells. Further experiments revealed that PVT1 promoted cell proliferation and suppressed cell apoptosis. Furthermore we also used the emerging technology, synthetic biology, to create tetracycline-inducible small hairpin RNA (shRNA) vectors which silenced PVT1 in a dosage-dependent manner to inhibit the progression of bladder cancer. In conclusion, data suggest that PVT1 could be an oncogene and may be a therapeutic target in bladder cancer. Synthetic "tetracycline-on" switch system can be used to quantitatively control the expression of PVT1 in bladder cancer in response to different concentration of doxycycline to suppress the progression of bladder cancer.
Highlights
Bladder cancer is one of the most common leading causes of cancer-related death in the world [1, 2]
We found that PVT1 was upregulated in bladder cancer tissues and cells, and functioned as an oncogene in bladder cancer. small hairpin RNA (shRNA) sequences targeting PVT1 controlled by synthetic “tetracycline-on” switch suppressed the expression of PVT1 in response to different concentration of doxycycline and inhibited progression of bladder cancer
As a famous oncogene in other cancer, PVT1 is located in chromosome 8q24 and is closely near MYC which promotes progression of bladder cancer [22, 23]
Summary
Bladder cancer is one of the most common leading causes of cancer-related death in the world [1, 2]. Recent studies suggest many oncogenes and tumor suppressors including long non-coding RNAs (lncRNAs) are key regulators for bladder cancer development. It indicates that lncRNAs may be novel indicators for treatment of bladder cancer. Long non-coding RNAs (lncRNAs), which are greater than 200 nucleotides in length, involve in the development of various human diseases, especially in cancers [5,6,7,8,9]. PVT1 overexpression acts independently of MYC to promote cell proliferation and suppress apoptosis in ovarian and breast cancer [15]. Whether PVT1 participates in development of bladder cancer is still unknown and needed to be studied
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
